These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 35534674)
41. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Cheung YK; Cheng SH; Chan EJ; Lo SV; Ng MH; Kwan P Epilepsia; 2013 Jul; 54(7):1307-14. PubMed ID: 23692434 [TBL] [Abstract][Full Text] [Related]
42. Association of John S; Balakrishnan K; Sukasem C; Anand TCV; Canyuk B; Pattharachayakul S J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442381 [TBL] [Abstract][Full Text] [Related]
43. [Pharmacogenetic research in the association between human leukocyte antigen and adverse drug reactions]. Xiong Y; Zhang W; Chen X Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 39(7):749-57. PubMed ID: 25080918 [TBL] [Abstract][Full Text] [Related]
44. Research on Susceptible Genes and Immunological Pathogenesis of Cutaneous Adverse Drug Reactions in Chinese Hans. Yang F; Yang Y; Zhu Q; Chen SA; Fu X; Yan S; Meng C; Ma L; Sun X; Xu J; Luo X; Xing Q J Investig Dermatol Symp Proc; 2015 Jul; 17(1):29-31. PubMed ID: 26067314 [TBL] [Abstract][Full Text] [Related]
45. HLA-B Min FL; Mao BJ; Zheng ZZ; He N; Fan CX; Cai RY; Wang J; Ou YM; Qin B; Liao WP; Yi YH; Li Z; Shi YW Front Neurol; 2019; 10():614. PubMed ID: 31263447 [TBL] [Abstract][Full Text] [Related]
46. Genetic basis for idiosyncratic reactions to antiepileptic drugs. Franciotta D; Kwan P; Perucca E Curr Opin Neurol; 2009 Apr; 22(2):144-9. PubMed ID: 19262378 [TBL] [Abstract][Full Text] [Related]
47. A highlight on carbamazepine-induced adverse drug reactions in Saudi Arabia: a retrospective medical records-based study. Sukkarieh HH; Khokhar AA; Bustami RT; Karbani GA; Alturki FA; Alvi SN Naunyn Schmiedebergs Arch Pharmacol; 2023 Nov; 396(11):3177-3182. PubMed ID: 37199768 [TBL] [Abstract][Full Text] [Related]
48. Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach. Tan-Koi WC; Sung C; Chong YY; Lateef A; Pang SM; Vasudevan A; Aw D; Lui NL; Lee SX; Ren EC; Koay ES; Tay YK; Lim YL; Lee HY; Dong D; Loke C; Tan L; Limenta M; Lee EJ; Toh D; Chan CL Pharmacogenomics; 2017 Jun; 18(9):881-890. PubMed ID: 28594314 [TBL] [Abstract][Full Text] [Related]
49. The pharmacogenomics of epilepsy. Franco V; Perucca E Expert Rev Neurother; 2015 Oct; 15(10):1161-70. PubMed ID: 26327193 [TBL] [Abstract][Full Text] [Related]
50. Ancestry-based pharmacogenomics, adverse reactions and carbamazepine: is the FDA warning correct? Payne PW Pharmacogenomics J; 2014 Oct; 14(5):473-80. PubMed ID: 24752310 [TBL] [Abstract][Full Text] [Related]
51. Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. Gerogianni K; Tsezou A; Dimas K Mol Diagn Ther; 2018 Jun; 22(3):297-314. PubMed ID: 29564734 [TBL] [Abstract][Full Text] [Related]
52. HLA-B*1502 allele is associated with a cross-reactivity pattern of cutaneous adverse reactions to antiepileptic drugs. Wang J; Zhang J; Wu X; Yu P; Hong Z J Int Med Res; 2012; 40(1):377-82. PubMed ID: 22429379 [TBL] [Abstract][Full Text] [Related]
53. Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation. Su SC; Hung SI; Fan WL; Dao RL; Chung WH Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27854302 [TBL] [Abstract][Full Text] [Related]
55. Lamotrigine drug interactions in combination therapy and the influence of therapeutic drug monitoring on clinical outcomes in paediatric patients. Koristkova B; Grundmann M; Brozmanova H; Kacirova I Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):26-33. PubMed ID: 30681278 [TBL] [Abstract][Full Text] [Related]
56. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Shi YW; Min FL; Zhou D; Qin B; Wang J; Hu FY; Cheung YK; Zhou JH; Hu XS; Zhou JQ; Zhou LM; Zheng ZZ; Pan J; He N; Liu ZS; Hou YQ; Lim KS; Ou YM; Hui-Ping Khor A; Ng CC; Mao BJ; Liu XR; Li BM; Kuan YY; Yi YH; He XL; Deng XY; Su T; Kwan P; Liao WP Neurology; 2017 Jun; 88(23):2183-2191. PubMed ID: 28476759 [TBL] [Abstract][Full Text] [Related]
57. Clinical implementation of preemptive pharmacogenomics in psychiatry. Skokou M; Karamperis K; Koufaki MI; Tsermpini EE; Pandi MT; Siamoglou S; Ferentinos P; Bartsakoulia M; Katsila T; Mitropoulou C; Patrinos GP; EBioMedicine; 2024 Mar; 101():105009. PubMed ID: 38364700 [TBL] [Abstract][Full Text] [Related]
58. Pharmacogenomics and adverse drug reactions: Primetime and not ready for primetime tests. Khan DA J Allergy Clin Immunol; 2016 Oct; 138(4):943-955. PubMed ID: 27720019 [TBL] [Abstract][Full Text] [Related]
59. Clinical application of pharmacogenomics: the example of HLA-based drug-induced toxicity. Lee MT; Mahasirimongkol S; Zhang Y; Suwankesawong W; Chaikledkaew U; Pavlidis C; Patrinos GP; Chantratita W Public Health Genomics; 2014; 17(5-6):248-55. PubMed ID: 25341524 [TBL] [Abstract][Full Text] [Related]
60. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Nevitt SJ; Tudur Smith C; Weston J; Marson AG Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001031. PubMed ID: 29952431 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]